1. Home
  2. TAP vs NUVL Comparison

TAP vs NUVL Comparison

Compare TAP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Molson Coors Beverage Company Class B

TAP

Molson Coors Beverage Company Class B

HOLD

Current Price

$46.56

Market Cap

10.1B

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$99.24

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAP
NUVL
Founded
1873
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
8.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TAP
NUVL
Price
$46.56
$99.24
Analyst Decision
Hold
Strong Buy
Analyst Count
16
15
Target Price
$50.31
$135.33
AVG Volume (30 Days)
3.1M
443.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.85
N/A
Revenue Next Year
$0.14
$1,064.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$42.94
$55.54
52 Week High
$64.66
$113.02

Technical Indicators

Market Signals
Indicator
TAP
NUVL
Relative Strength Index (RSI) 38.80 42.84
Support Level $45.23 $98.65
Resistance Level $47.69 $107.13
Average True Range (ATR) 1.45 4.05
MACD -0.45 -0.31
Stochastic Oscillator 6.98 19.28

Price Performance

Historical Comparison
TAP
NUVL

About TAP Molson Coors Beverage Company Class B

Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: